These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36287936)

  • 1. Botulinum Toxin, a Drug with Potential Interest for Dentists-An Introduction.
    Bakke M
    Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.
    Dadgardoust PD; Rosales RL; Asuncion RM; Dressler D
    J Neural Transm (Vienna); 2019 Feb; 126(2):141-148. PubMed ID: 30604200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System.
    Yoshida K
    Toxins (Basel); 2022 Apr; 14(4):. PubMed ID: 35448891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Botulinum Toxin Therapy on Health-Related Quality of Life Evaluated by the Oromandibular Dystonia Rating Scale.
    Yoshida K
    Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Botulinum Toxin Type A on Pain among Trigeminal Neuralgia, Myofascial Temporomandibular Disorders, and Oromandibular Dystonia.
    Yoshida K
    Toxins (Basel); 2021 Aug; 13(9):. PubMed ID: 34564609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features.
    Yoshida K
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30658420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
    Braun T; Gürkov R; Hempel JM; Berghaus A; Krause E
    Eur Arch Otorhinolaryngol; 2010 Dec; 267(12):1963-7. PubMed ID: 20563590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Use of Botulinum Toxin Therapy for Focal and Task-Specific Dystonias.
    Lungu C; Ahmad OF
    Semin Neurol; 2016 Feb; 36(1):41-6. PubMed ID: 26866495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-oriented approach to botulinum toxin use.
    Jankovic J
    Toxicon; 2009 Oct; 54(5):614-23. PubMed ID: 19073203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oromandibular dystonia associated with SCA36.
    Miyashiro A; Sugihara K; Kawarai T; Miyamoto R; Izumi Y; Morino H; Maruyama H; Orlacchio A; Kawakami H; Kaji R
    Mov Disord; 2013 Apr; 28(4):558-9. PubMed ID: 23390045
    [No Abstract]   [Full Text] [Related]  

  • 14. Botulinum toxin type A treatment of four cases of Wilson disease with lower limb dystonia: A prospective study.
    Cao Z; Rao R; Wu T; Chen S; Xing S; Han Y
    Toxicon; 2023 Jan; 221():106959. PubMed ID: 36343759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias.
    Rosales RL; Santos MM; Ng AR; Teleg R; Dantes M; Lee LV; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():35-43. PubMed ID: 21244305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxins in the treatment of primary focal dystonias.
    Truong D
    J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New trends in the science of botulinum toxin-A as applied in dystonia.
    Pickett A; Rosales RL
    Int J Neurosci; 2011; 121 Suppl 1():22-34. PubMed ID: 21244295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BoNT clinical trial update: Sialorrhea.
    Tamadonfar ET; Lew MF
    Toxicon; 2023 Apr; 226():107087. PubMed ID: 36931440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.
    Hilker R; Schischniaschvili M; Ghaemi M; Jacobs A; Rudolf J
    J Neurol Neurosurg Psychiatry; 2001 Aug; 71(2):193-9. PubMed ID: 11459891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oromandibular dystonia, mental distress and oro-facial dysfunction-A follow-up 8-10 years after start of treatment with botulinum toxin.
    Bakke M; Baram S; Dalager T; Biernat HB; Møller E
    J Oral Rehabil; 2019 May; 46(5):441-449. PubMed ID: 30664806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.